Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bridged Bicyclo Compounds, Heterocyclic
/ adverse effects
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ diagnosis
Lymphoma, B-Cell
Protein Kinase Inhibitors
/ adverse effects
Purines
Quinazolinones
Sulfonamides
Relapsed/refractory chronic lymphocytic leukemia
anti-CD19 antibody
idelalisib
phase II study
tafasitamab
venetoclax
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
21
8
2021
medline:
15
4
2022
entrez:
20
8
2021
Statut:
ppublish
Résumé
Patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) whose treatment failed with a Bruton's tyrosine kinase inhibitor have poor outcomes. We investigated tafasitamab plus idelalisib (cohort A) or venetoclax (cohort B) in this patient population in a phase II study (NCT02639910). In total, 24 patients were enrolled (cohort A:
Identifiants
pubmed: 34414843
doi: 10.1080/10428194.2021.1964020
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Bridged Bicyclo Compounds, Heterocyclic
0
Protein Kinase Inhibitors
0
Purines
0
Quinazolinones
0
Sulfonamides
0
venetoclax
N54AIC43PW
tafasitamab
QQA9MLH692
idelalisib
YG57I8T5M0
Banques de données
ClinicalTrials.gov
['NCT02639910']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM